AMA, states continue data mining alternatives

While data mining laws are mired in court, alternatives are helping physicians control rep encounters and help states manage costs.

The Physician Data Restriction Program (PDRP), the American Medical Association data opt-out plan, is drawing sign-ups at a rate of 120-130 per week, according to Jeremy Lazarus, MD, member, AMA Board of Trustees, and speaker, House of Delegates. About 65% of its 12,000 enrollees have come from outside AMA's 240,000-member base. Drug companies still get access to the data, and the ability to use information for academic and other research purposes is maintained.

Courts have ruled against laws in New Hampshire and Maine. At press time, both were on appeal, while Vermont had tweaked its law to avoid a similar fate but kept data mining restrictions in tact.

After New Hampshire, “States went in other directions to manage cost and quality…such as preferred drug lists,” said Randy Frankel, VP for external affairs, IMS Health. “Others are experimenting with academic detailing efforts, which by the way are driven by provider-level data.”

Minnesota's physician gift reporting laws, California's codifying of voluntary marketing guidelines and the District of Columbia's tack to license sales reps are among other alternatives. 

You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.